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Abstract Multidrug resistance (MDR) is a major obstacle to
the treatment of small cell lung cancer (SCLC). EPHA3 has
been revealed to be the most frequently mutated Eph receptor
gene in lung cancer with abnormal expression. Growing evi-
dence indicates that the signaling proteins of EPHA3 down-
stream, including PI3K, BMX and STAT3, play crucial roles
in tumorigenesis and cancer progression. To explore the pos-
sible role of EPHA3 in MDR, we assessed the influence of
EPHA3 on chemoresistance, cell cycle, apoptosis, and tumor
growth, as well as the relationship between EPHA3 and the
expression of PI3K, BMX, and STAT3 in SCLC.We observed
that overexpression of EPHA3 in SCLC cells decreased
chemoresistance by increasing apoptosis and inducing G0/
G1 arrest, accompanied by reduced phosphorylation of
PI3K/BMX/STAT3 signaling pathway. Knockdown of
EPHA3 expression generated a resistant phenotype of
SCLC, as a result of decreased apoptosis and induced G2/M
phase arrest. And re-expression of EPHA3 in these cells
reversed the resistant phenotype. Meanwhile, increased
phosphorylation of PI3K/BMX/STAT3 signaling path-
way was observed in these cells with EPHA3 deficiency.
Notably, both PI3K inhibitor (LY294002) and BMX inhibitor
(LFM-A13) impaired the chemoresistance enhanced by
EPHA3 deficiency in SCLC cell lines. Furthermore, EPHA3
inhibited growth of SCLC cells in vivo and was correlated
with longer overall survival of SCLC patients. Thus, we first
provide the evidences that EPHA3 is involved in regulating
the MDR of SCLC via PI3K/BMX/STAT3 signaling and may
be a new therapeutic target in SCLC.
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Introduction
Lung cancer is the leading cause of cancer-related death
worldwide (World Health Organization. Cancer. 2012;
http://globocan.iarc.fr). Among lung cancer types, small
cell lung cancer (SCLC), the undifferentiated type, accounts
for approximately 15 % of cases. The extreme aggressiveness
and poor prognosis of SCLC are mainly due to its early and
widespread metastases and development of multidrug
resistance (MDR) to chemotherapy [1–4]. Mechanisms of
MDR include decreased drug accumulation, drug inactivation,
enhanced DNA repair, and abnormal cell apoptosis pathways.
However, the molecular mechanisms involved in MDR pro-
cesses of SCLC are not fully understood.
The Eph receptor family is the largest subgroup of the
receptor tyrosine kinase (RTK) family. Eph receptors and their
membrane-bound ligands, the ephrins, play critical roles in
embryonic development, postnatal growth and pathogenesis
[5–7]. The Eph receptor family is composed of two subclasses
(A and B) and 16 members (A1-A10, B1-B6). EPHA3
(3p11.2) encodes a transmembrane protein with 983 amino
acids that is widely expressed during embryonic development,
overexpressed in the nervous system and heart, and exhibits
lower expression in the brain, lung, bladder, prostate, and
colon [8–13]. Studies have shown that EPHA3 exhibits ab-
normal expression in a variety of tumors, such as colorectal
carcinoma, glioblastoma multiforme, melanoma, and hepato-
cellular carcinoma [14–17]. A recent collaborative study of
188 lung adenocarcinomas by Ding et al. revealed that
EPHA3 is the Eph receptor found to be most frequently mu-
tated in lung cancer, with 19 missense mutations identified so
far and a mutation rate of 6 % [18]. Zhuang et al. further
investigated the EPHA3 mutations and identified an EPHA3
mutation-associated gene signature in lung cancer that was
associated with poor patient survival. Moreover, EPHA3 gene
copy numbers and/or expression levels were decreased in tu-
mors from large cohorts of patients with lung cancer. Re-
expression of wild-type EPHA3 in human lung cancer lines
increased apoptosis by suppression of AKT activation in vitro
and inhibited the growth of tumor xenografts [19]. Although
Ross et al. detected 98 SCLC samples by next-generation
sequencing and found amplifications of EPHA3 genes in three
cases of SCLC [20], EPHA3 associated with SCLC has rarely
been published previously and little is known about the role of
EPHA3 genes in chemoresistance.
RTKs, which are the major regulators of signal trans-
duction pathways, are associated with cellular prolifera-
tion, apoptosis, and tumorigenesis. It is well documented
that RTKs are involved in regulating the main functions of
cells though the phosphatidylinositol-3 kinase (PI3K) sig-
naling pathway [21, 22]. The PI3Ks are a family of intra-
cellular lipid kinase enzymes, including class I, II, and III
enzymes, which control a core cellular signaling and
regulatory network and play a pivotal role in metabo-
lism, growth, and survival in the cell. Class I PI3Ks are
further divided into subclass IA (PI3Kα, PI3Kβ, and
PI3Kδ isoforms) and IB (PI3Kγ isoform). PI3Kα is a
heterodimer consisting of one regulatory subunit (p85α,
encoded by PIK3R1) and one 110-kDa catalytic subunit
(p110α, encoded by PIK3CA) that receives regulatory
stimuli from transmembrane receptors via tyrosine ki-
nase. In the p110α/p85α-PI3K complex, p85α is neces-
sary for the cellular stability of PI3Kα and the nSH2
domain of p85 specifically interacts with the kinase do-
main of the EPH receptor [23–29].
Bone marrow kinase in chromosome X (BMX), a non-
receptor tyrosine kinase member of the Tec kinase family,
contains a PH-like domain that mediates membrane targeting
by binding to phosphatidylinositol 3,4,5-triphosphate (PIP3)
and an SH2 domain that binds to tyrosine-phosphorylated
proteins and functions in signal transduction [30–32]. BMX
was confirmed to be a critical downstream target of the con-
stitutively active PI3-kinase in PTEN-deficient prostate cancer
cells, and BMX was shown to activate the signal transducer
and activator of transcription 3 (STAT3) signaling to maintain
self-renewal and tumorigenic potential of glioblastoma stem
cells [33, 34]. Activation of STAT3 was shown to be closely
associated with cell apoptosis. STAT3 positively regulates cell
survival by inducing Bcl-2 and Bcl-XL to repress apoptosis;
inversely, STAT3 degradation and inhibition causes increased
apoptosis [35–39]. Whether EPHA3 influenced cell apoptosis
potentially through PI3K/BMX/STAT3 signaling to modulate
MDR of SCLC is still unclear.
To better understand the biological function of EPHA3 in
SCLC, we investigated its potential role in tumor growth and
chemoresistance through loss- and gain-of-function ap-
proaches in human SCLC cell lines (H69, H69AR, H446,
H146, and H1688). Moreover, we investigated the relation-
ship between EPHA3 expression and the expression of
PI3K/BMX/STAT3 signaling pathway. Finally, we detected
EPHA3 expression in human SCLC tissues and evaluated
the relevance of EPHA3 expression with clinical prognosis
of SCLC patients. Therefore, we sought to identify the role
of EPHA3 in SCLC progression and chemoresistance and its
potential signaling pathway.
Materials and methods
Cell culture The human SCLC cell line NCI-H69 and the
drug-resistant sublines NCI-H69AR, NCI-H446, NCI-H146,
and NCI-H1688 were purchased from the American Type
Culture Collection (ATCC; Rockville, MD, USA) and main-
tained in RPMI 1640 medium (HyClone, Logan, UT, USA)
with 10 % fetal calf serum (HyClone) in an incubator at 37 °C
with 5 % CO2. The H69AR subline was maintained in a
11960 Tumor Biol. (2016) 37:11959–11971
5 μg/L final concentration of doxorubicin (Jiangshu, China)
and transferred to drug-free media for at least 2 weeks before
any experiment.
Cell transfection For stable transfections, which were select-
ed for follow-up study, the EPHA3 expression plasmid
EPHA3-PEX2-EcoRI/BamHI and the EPHA3-PEX2 empty
plasmid (Genepharma, Shanghai, China), as well as the
EPHA3-short hairpin RNA (shRNA) and the EPHA3
shRNA negative control (Genepharma), respectively, were
transfected into NCI-H69, NCI-H69AR, NCI-H446, NCI-
H146, and NCI-H1688 cells using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) and OPTI-MEM (Gibco,
Gland Island, NY, USA).
RNA isolation and quantitative reverse transcription-
PCR Total RNA was isolated from cell lines using RNAiso
Plus (Takara, Dalian, China) according to the manufacturer’s
instructions and the concentration of RNA was determined
using a NanoDrop 2000 spectrophotometer (Thermo
Scientific, Rockford, IL, USA). cDNA synthesis was carried
out according to the PrimeScript RT reagent Kit with gDNA
Eraser (Takara). qRT-PCR for EPHA3 was performed in trip-
licate with SYBR Premix Ex TaqTM II (Takara) on an
Illumina-Eco Real-Time PCR System (illumina, San Diego,
CA, USA) using the following primers: human EPHA3
forward, 5′-GTTCTCTGGGAGGTGATGTCTT-3′ and re-
verse, 5′-GGGTCTGTTGTTCCTGTCTTTC-3′ (Sangon
Biotech, Inc., Shanghai, China); GAPDH (endogenous
control) forward, 5′-AGAAGGCTGGGGCTCATTTG-3′
and reverse, 5 ′-AGGGGCCATCCACAGTCTTC-3 ′
(Sangon Biotech, Inc.).
Western blotting analysis Total protein was isolated with
a total protein extraction kit (Keygene, Nanjing, China)
and quantitated using a BCA assay kit (Keygene). The
protein lysates were separated using 8 or 10 % SDS-
PAGE gels and electrophoretically transferred to
polyvinylidene difluoride (PVDF) membranes. After an-
tigen blocking, the transferred PVDF membrane was
incubated with primary antibodies for EPHA3 (clone
3A12, 3.5 μg/mL, Abnova, Taiwan), phospho-PIK3R1
(pTyr467, 1:500, Sigma-Aldrich, St. Louis, MO, USA),
total PI3K p85α (clone Ab6, 1 μg/mL, Abcam,
Cambridge, England), phospho-BMX (Tyr40, 1:1000,
Cell Signaling technology), total BMX (Y396, 1:1000,
Abcam, Cambridge, England), phospho-Stat3 (Tyr705,
D3A7, 1:1000, Cell Signaling technology), total STAT3
(clone 4D6, 10 μg/mL, Abnova), and GAPDH (internal
control, 1D4, 1:1000, EarthOx, San Francisco, CA,
USA) overnight at 4 °C with gentle shaking. The sec-
ondary goat anti-Rabbit-IgG (EarthOx) or goat anti-
Mouse-IgG (EarthOx) HRP AffiniPure antibody was
added correspondingly at a 1:2000 dilution. After chemilumi-
nescence, the intensity of the protein fragments was quantified
using Quantity One software (4.5.0 basic, Bio-Rad
Laboratories, Hercules, CA, USA).
Cell counting kit-8 (CCK-8) assay Cells were reseeded in
96-well plates at 5× 103 cells per well for NCI-H69, NCI-
H69AR, NCI-H446, and NCI-H1688 and 20×103 cells per
well for NCI-H146. After adherence of stably transfected
cells, cells were treated with drugs for 24 h. A total of three
chemotherapy drugs [Adriamycin (ADM; Jiangshu, China),
Cisplatin (DDP; Shandong, China), and Etoposide (VP-16;
Jiangshu, China)] were used with different drug concentration
gradients. The absorbance at 450 nm was measured after in-
cubation with 10 μL CCK-8 reagent (Dojindo, Kumamato,
Japan) for 4 h. The cells incubated without drugs were set at
100 % survival and were used to calculate the IC50 (ug/mL)
concentration for each chemotherapeutic drug. The assay was
conducted in five replicate wells for each sample and three
independent experiments were performed.
Flow cytometric analysis Cells were treated with ADM
(4.6 μM), DDP (16.7 μM), and VP-16 (34 μM) [40] for
24 h and then kept in drug-free media for 6 h. Cells were
collected for the early apoptosis assay performed using an
Annexin V/propidium iodide detection kit (Becton-
Dickinson (BD), San Jose, CA, USA) on a FACSCalibur sys-
tem (BD). For the cell-cycle assay, the cells were collected and
fixed in 70 % ethanol at 4 °C for 16 h and then stained with
propidium iodide. Cellquest Pro software was used for apo-
ptosis analysis and ModFit LT software was used for the anal-
ysis of the cell cycle. Cells in the quadrant of Annexin V−PI−
(lower left) represent viable cells, cells in the quadrant of
Annexin V−PI+ (upper left) represent necrotic cells, cells in
the quadrant of Annexin V+PI+ (upper right) represent late
apoptotic and dead cells, and cells in the quadrant of
Annexin V+PI− (lower right) represent early apoptotic cells.
Generally, apoptosis analysis is based mainly on the percent-
age of Annexin V+PI− cells. All assays were carried out inde-
pendently in triplicate.
Clinical samples and immunohistochemistry Sixty-one
SCLC tumor tissues and 25 normal lung tissues were obtained
from the Armed Police Hospital of Guangdong Province and
the Third Affiliated Hospital of Guangzhou Medical
University. All samples were confirmed as SCLC by patho-
logic examination, and tumor staging was further distin-
guished as limited disease (20 cases) versus extensive disease
(41 cases) according to the Veterans Administration Lung
Cancer Study Group system. Immunohistochemistry was
performed under antigen retrieval conditions in 2-mM
citric acid, 10-mM sodium citrate buffer, and at pH 6.0.
Endogenous peroxidase was blocked by 3 % H2O2 for
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30 min, and the sections were stained with rabbit polyclon-
al antibody against human EPHA3 (1: 400; Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Negative controls
were performed by replacing the primary antibodies stated
above with PBS. Stained sections were analyzed indepen-
dently by two different pathologists. Positively stained
EPHA3 was primarily located in the cytoplasm of cells
and appeared as light brown and brown particles. The in-
tensity of staining was scored manually (high, 3; medium,
2; low, 1; no staining, 0). The extent of staining was scored
as 0 (0–10 %), 1 (11–25 %), 2 (26–50 %), or 3 (51–100 %),
according to the percentages of the positive stained area in
relation to the entire carcinoma-involved area or the entire
normal sample area. The sum of the intensity and extent
scores was used as the final staining score (0–6). Optimal
cut off values were identified; a final staining score ≤1
indicated negative expression (−) and a final staining score
≥1 indicated positive expression (+).
In vivo tumor growth Male BALB/c nude mice aged 30–
40 days (purchased from the Medical Experimental Animal
Center of Guangdong Province, China) were raised under
pathogen-free conditions. All procedures were performed ac-
cording to the guidelines of the Association for Assessment
and Accreditation of Laboratory Animal Care International.
Cells in RPMI-1640 medium were subcutaneously inoculated
into the shoulder-back of nude mice in the light of 1×107/
0.1 mL/site to establish the tumor model. The tumor volume
was determined every 3 days over the course of 21 days by
direct measurement with a sliding caliper and calculated by
the equation (V=0.4× ab2, where a is the widest diameter of
the tumor and b is the diameter perpendicular to a) to construct
the growth curves of the tumors. Twenty-one days later, the
mice were sacrificed and tumors were excised. Half of the
tumor tissues were fixed with neutral phosphate-
buffered formalin, followed by immunohistochemical
examination. The other half of the tumors were washed
Fig. 1 Overexpression of EPHA3 reinforced the chemosensitivity in
SCLC cell lines. The differential expression of EPHA3 was assessed in
H69, H69AR, H446, H146, and H1688 cells by qRT-PCR (a) and
Western blotting (b). The higher expression of EPHA3 was detected in
H69, H69AR, H446, H146, and H1688 cells transfected with plasmid
EPHA3-PEX2-EcoRI/BamHI by qRT-PCR (a) and Western blotting (b)
compared with mock and NC. The drug sensitivity of SCLC cell lines
displayed as the IC50 values were measured in these SCLC cell lines after
treatment with ADM, DDP, or VP-16 using the CCK-8 assay.
Overexpression of EPHA3 in these SCLC cell lines led to a significant
reduction in the IC50 values (c)
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with pre-chilled PBS, and the total protein of the tumors
was isolated for subsequent Western blotting examina-
tion of p-STAT3 and total STAT3 protein.
Statistical analysisAll data are shown as the mean± standard
deviation and were generated using SPSS 19.0 statistical soft-
ware. One-way ANOVA analyses, χ2 test, Kaplan-Meier sur-
vival analyses, and Cox regression analyses were used.
P<0.05 was considered significant.
Results
Overexpression of EPHA3 reinforces a sensitive pheno-
type To investigate the effect of EPHA3 on SCLC
chemoresistance, the expression of EPHA3 was initially de-
tected in SCLC drug-resistant cells (H69AR) and drug-
sensitive cells (H69, H446, H146, and H1688) by qRT-PCR
and Western blotting. We found that EPHA3 expression at
both the mRNA and protein level was significantly higher in
H69 and H1688 cells than in H69AR, H446, and H146 cells
(P<0.05; Fig. 1a, b).We then transfected all 5 SCLC cell lines
with the plasmid EPHA3-PEX2-EcoRI/BamHI, and the over-
expression of EPHA3 in these cells was confirmed by qRT-
PCR and Western blotting (**P<0.05; Fig. 1a, b). CCK-8
assay revealed a significant reduction of IC50 values and in-
creased sensitivity to ADM, DDP, or VP-16 in these cells
transfected with EPHA3-PEX2-EcoRI/BamHI comparedwith
relevant NC and mock cells (**P<0.05; Fig. 1c). In addition,
a significant induction of cell early apoptosis and G0/G1 cell-
cycle arrest was observed in H69AR (P<0.05; Fig. 2a, d),
H446 (P<0.05; Fig. 2b, e), and H146 cells with EPHA3 over-
expression (P<0.05; Fig. 2c, f; Supplementary Figure S1) by
flow cytometry analysis. These findings suggested that
EPHA3 sensitizes SCLC cells to chemotherapy drugs, and
possibly plays critical roles in chemoresistance of SCLC cells.
Knockdown of EPHA3 results in a resistant phenotype To
further verify the effect of EPHA3 on SCLC chemoresistance,
we subsequently transfected SCLC cells with EPHA3
shRNAs (EPHA3-1690, −1286, −2635, −2934) and NC to
knockdown the expression of EPHA3, and shRNA-1690 for
H69 and H69AR cells, as well as −2934 for H446, H146, and
H1688 cells (Supplementary Figure S2). The cells which
showed the most significant inhibition were selected for
follow-up study. All 5 SCLC cell lines transfected with
EPHA3 shRNAs showed decreased expression of EPHA3
both at the mRNA and protein levels compared with relevant
NC and mock cells (**P<0.05; Fig. 3a, b). The IC50 values
of drug-sensitive SCLC cells (H69, H446, H146, and H1688
cells) treated with chemotherapeutic drugs were significantly
increased with the EPHA3 deficiency, while the drug-
resistance of H69AR cells was further enhanced (**P<0.05;
Fig. 3c). Furthermore, we found that EPHA3 deficiency led to
decreased cell apoptosis and induced G2/M cell-cycle arrest in
H69 (P<0.05; Fig. 4a, c) and H1688 cells (P<0.05; Fig. 4b,
d; Supplementary Figure S3) treated with the chemotherapeu-
tic drugs stated above. As expected, the knockdown of
EPHA3 results in the formation of a resistant phenotype in
SCLC cell lines.
To further determine whether EPHA3 indeed exerts its
function on SCLC chemoresistance, we conducted the rescue
Fig. 2 Overexpression of EPHA3 induced the cell early apoptosis rate and G0/G1 phase arrest. H69AR (a, d), H446 (b, e), and H146 (c, f) cells
transfected with plasmid EPHA3-PEX2-EcoRI/BamHI or NC were detected by flow cytometric analysis after treatment with ADM, DDP, or VP-16
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experiment by co-transfecting the stably silenced cells (H69
EPHA3 shRNA and H1688 EPHA3 shRNA) and their corre-
sponding EPHA3 shRNA NC cells with the plasmids
EPHA3-PEX2-EcoRI/BamHI and EPHA3-PEX2NC, respec-
tively. As shown in Fig. 5, the downregulated expression of
EPHA3 in H69 and H1688 cells was re-expressed at both the
mRNA and protein level after co-transfection by qRT-PCR
(**P < 0.05; Fig. 5a) and Western blotting (**P < 0.05;
Fig. 5b). Flow cytometric analysis was conducted to test for
cell apoptosis induced by chemotherapeutic drugs after co-
transfection. In contrast to the reduction of cell apoptosis rate
in H69 and H1688 cells caused by EPHA3 deficiency, the rate
of cell apoptosis increased after co-transfection compared
with mock cells and NC cells (***P < 0.05; Fig. 5c;
Supplementary Figure S4), respectively. Collectively, these
results suggested that EPHA3 has a reliable influence on the
regulation of MDR in SCLC cell lines through the cell apo-
ptosis pathway.
EPHA3 modulates the protein expression of the
PI3K/BMX/STAT3 signaling pathway The above observa-
tions prompted us to investigate the potential downstream
signaling pathway of EPHA3 in chemoresistance of SCLC.
To explore the modulation mechanisms of EPHA3 on MDR
through the cell apoptosis pathway, we performed Western
blotting analyses to further investigate whether EPHA3 was
potentially involved in signaling through the PI3K/BMX/
STAT3 pathway. The results showed that overexpression of
EPHA3 in H69AR, H446, and H146 cells downregulated the
expression of p-PI3K-p85α, p-BMX, total BMX, and p-
STAT3 (P<0.05), whereas knockdown of EPHA3 in H69
and H1688 cells increased the expression of p-PI3K-p85α,
p-BMX, total BMX, and p-STAT3 protein levels (P<0.05;
Fig. 6a; Supplementary Figure S5). However, there was no
significant difference in total PI3K-p85α and total STAT3
expression. These findings demonstrated that EPHA3 signif-
icantly reduces the phosphorylation of PI3K/BMX/STAT3 in
Fig. 3 Knockdown of EPHA3 enhanced chemoresistance of SCLC cell
lines. A significant EPHA3 deficiency was detected in these SCLC cell
lines transfected with EPHA3 shRNA by qRT-PCR (a) and Western
blotting (b). CCK-8 assay showed that knockdown of EPHA3 in these
SCLC cell lines significantly increased the IC50 values (c)
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SCLC cell lines. Interestingly, the expression level of p-
STAT3 was observed to be negatively correlated with the cell
early apoptosis rate induced by the three chemotherapeutic
drugs in the SCLC cell lines (2-tailed Pearson correlation,
r=−0.786, −0.742, −0.805; P<0.05; Fig. 6b–d), which was
consistent with the conclusions stated above.
To further determine whether EPHA3 indeed regulates the
expression of PI3K/BMX/STAT3 signaling pathway, the
Fig. 4 Knockdown of EPHA3
resulted in a reduced early
apoptosis rate and G2/M cell-
cycle arrest. Cell apoptosis and
cell cycle were assayed by flow
cytometric analysis after H69 (a,
c) and H1688 (b, d) cells with
EPHA3 deficiency were treated
with ADM, DDP, or VP-16
Fig. 5 Re-expression of EPHA3 increased the cell early apoptosis rate in
SCLC cell lines. After co-transfection, the expression of EPHA3 in H69
and H1688 cells with EPHA3 deficiency was detected to be re-expressed
at both themRNA and protein level by qRT-PCR (a) andWestern blotting
(b). In addition, after co-transfection, the cell early apoptosis rate of these
EPHA3 deficiency cells was detected to be increased by flow cytometric
analysis following treatment with ADM, DDP, or VP-16, in comparison
with mock and NC cells, respectively (c)
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PI3K-specific inhibitor LY294002 was used to block
PI3K/BMX pathway. The results showed that the increased
expression of p-BMX and p-STAT3 protein levels induced by
EPHA3 shRNA were reduced, even vanished significantly
both in H69 and H1688 cells (P < 0.05; Fig. 7a;
Supplementary Figure S6). The expression of p-PI3K-p85α
and total PI3K-p85α in the stably silenced cells simply
vanished under exposure to LY294002. We therefore
proceeded to block BMX/STAT3 pathway with the BMX
inhibitor LFM-A13. Similarly, LFM-A13 reversed the
overexpression of p-STAT3 caused by EPHA3 shRNA in
H69 and H1688 cells (P< 0.05; Fig. 7b; Supplementary
Figure S6) and led to the disappearance of p-BMX and
total BMX expression in these cells. We subsequently in-
vestigated the sensitivity of these stably silenced cells
treated with the inhibitors in response to the three chemo-
therapy drugs by CCK-8 assay. The IC50 values of the
stably silenced cells exposure to chemotherapeutic drugs
were significantly decreased with the inhibition of
PI3K/BMX or BMX/STAT3 pathway (P < 0.05; Fig. 7c,
d). Taken together, these data suggested that EPHA3 reg-
ulates chemoresistance of SCLC cells through affecting the
expression of PI3K/BMX/STAT3 pathway.
EPHA3 suppresses tumor growth of SCLC cell lines
in vivo To determine the effect of EPHA3 on tumor growth
potential in vivo, SCLC cells with altered expression of
EPHA3 were subcutaneously inoculated into BALB/C-nude
mice. Interestingly, the results showed that lower ex-
pression of EPHA3 significantly enhanced the ability
of tumor growth either in H69 cells compared to the
EPHA3 downregu la t ed ce l l s (mean H69 tumor
volumes=36 mm3 vs shRNA=1166 mm3, *P<0.05, t test;
Fig. 8a, b) or in H69AR, H446, and H146 cells compared to
corresponding EPHA3 upregulated cells (mean H69AR tumor
volumes=455 mm3 vs EPHA3=105 mm3, **P<0.05, t test,
Fig. 8a, b; mean H446 tumor volumes = 840 mm3 vs
EPHA3= 144 mm3, ***P< 0.05, t test, Fig. 8a, b; mean
H146 tumor volumes = 800 mm3 vs EPHA3 = 75 mm3,
****P<0.05, t test; Fig. 8a, b), with the exception of H1688
cells. Whether the expression of EPHA3 was upregulated or
downregulated in H1688 cells, there was no significant differ-
ence in tumor growth (mean H1688 tumor volumes=72 mm3
vs shRNA = 112 vs EPHA3 = 60 mm3, P> 0.05, t test;
Fig. 8a, b). Furthermore, the expression of EPHA3 in tumors,
affirmed by immunohistochemistry with 4° (the intensity of
staining: high, 3; medium, 2; low, 1; no staining, 0. Fig. 8c),
Fig. 6 The protein expression of PI3K/BMX/STAT3 was modulated by
the manipulation of EPHA3 expression in SCLC cell lines.
Overexpression of EPHA3 in H69AR, H446, and H146 cells resulted
in the decreased the expression of p-PI3K-p85α, p-BMX, total BMX,
and p-STAT3 by Western blotting. By contrast, knockdown of EPHA3
in H69 and H1688 cells increased expression of p-PI3K-p85α, p-BMX,
total BMX, and p-STAT3 protein levels (a). However, there was no
significant difference in total PI3K-p85α and total STAT3 expression
between the treatment groups. Furthermore, the expression level of p-
STAT3 was negatively correlated with the cell early apoptosis rate
induced by ADM (b), DDP (c), or VP-16 (d) in SCLC cell lines
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was observed to be negatively correlated with the ex-
pression level of p-STAT3 by Western blotting (2-tailed
Spearman correlation, r = −0.864, P < 0.05; Fig. 8d;
Supplementary Figure S7), but no correlation was ob-
served with the expression level of total STAT3 (2-tailed
Spearman correlation, P> 0.05).
EPHA3 expression is correlated with survival time of
SCLC patients To evaluate the clinicopathological features
of EPHA3 expression in SCLC, immunohistochemical
staining was performed in SCLC tissues and normal
lung tissues. EPHA3 expression was detectable in 18
of 25 (72 %) normal lung tissue samples (Fig. 9a),
compared with 21 of 61 (34.4 %) SCLC tumor samples
(*P < 0.05, χ2 test, Fig. 9b, c, Table 1). EPHA3
expression was correlated with the survival status of
patients (**P< 0.05, χ2 test; Table 1). However, no sig-
nificant differences were observed in EPHA3 expression
with respect to gender, age, and disease stage (P> 0.05,
χ2 test; Table 1). For overall survival, the Kaplan–Meier
method revealed that EPHA3 expression level (P< 0.05;
Fig. 9d) and disease stage (P< 0.05; Fig. 9e) were cor-
related with significant overall survival time of the 61
SCLC patients (Supplementary Table S1). Cox regres-
sion analysis indicated that disease stage and EPHA3
expression (P< 0.05; Fig. 9f) were found to be signifi-
cantly independent prognostic factors for the SCLC pa-
tients. EPHA3 expression was an independent predictor of
survival with a hazard ratio of 0.151 and a 95 % confidence
interval ranging from 0.060 to 0.378.
Fig. 7 The signaling pathway inhibitors blocked the effect of EPHA3
deficiency on SCLC chemoresistance. After the stably silenced cells (H69
and H1688 EPHA3 shRNA)were treated with the PI3K-specific inhibitor
LY294002 (10μM, Sigma-Aldrich) for 2 h, we detected the expression of
PI3K/BMX/STAT3 protein by Western blotting. The increased
expression of p-BMX and p-STAT3 protein levels induced by EPHA3
shRNA in H69 and H1688 cells was blocked by the inhibition of
PI3K/BMX pathway with LY294002 (a). The expression of p-PI3K-
p85α and total PI3K-p85α in the stably silenced cells simply vanished
under exposure to LY294002. Moreover, we evaluated the expression of
BMX/STAT3 protein in these stably silenced cells by Western blotting
following treatment with BMX inhibitor LFM-A13 (3 μM, Sigma-
Aldrich) for 2 h. In the same way, the increased expression of p-STAT3
protein levels induced by EPHA3 shRNA in H69 and H1688 cells was
blocked by LFM-A13 (b), accompanied by the disappearance of p-BMX
and total BMX expression. Even more, the IC50 values of the stably
silenced cells exposure to chemotherapeutic drugs were significantly
decreased by CCK-8 assay, whether treated with LY294002 or LFM-
A13 (c, d)
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Discussion
EphA3 was initially characterized during analysis of the reti-
notectal mapping of neurons [41] and was later found to be
expressed in embryonic development, brain, heart, lung, blad-
der, prostate, and colon [8–13]. With respect to its putative
role in tumorigenesis, previous studies have indicated that
EPHA3 can signal both in a kinase-dependent and kinase-
independent manner, inducing both tumor-promoting and
tumor-suppressing effects [42, 43]. In glioblastoma
multiforme, EPHA3 has exhibited highly expression in undif-
ferentiated mesenchymal cells and has been especially
assigned a kinase-independent oncogenic role based on its
modulating mitogen-activated protein kinase (MAPK) signal-
ing [15]. However, in a series of studies of non-small cell lung
cancer (NSCLC), EPHA3 was identified as a tumor suppres-
sor with decreased expression levels. The reduction in recep-
tor activity conferred by the point mutations of EPHA3 found
in cancers, and ligand- and EPHA3-dependent apoptosis of
tumor and stroma cells upon receptor agonist treatment sug-
gested that wild-type EPHA3 has anti-tumorigenic properties
in NSCLC [19, 43–46].
Given the opposing outcomes of aberrant EPHA3 expres-
sion in different tumors, as well as our previous results that the
expression of EPHA3 in H69AR was lower than in the parent
cell line H69, we proposed a hypothesis that EPHA3might be
involved in regulating the MDR of SCLC. In this study, we
manipulated the expression of EPHA3 through loss- and gain-
of-function approaches in 5 SCLC cell lines to explore the
drug resistance mediated by EPHA3. Both approaches clearly
indicated that EPHA3 improves chemosensitivity and sup-
presses tumor growth in vivo, which manifests that EPHA3
acts as a tumor suppressor in SCLC. Furthermore, higher ex-
pression levels of EPHA3 in SCLC tumor samples were cor-
related with longer overall survival of patients, implying that
EPHA3 might be associated with chemosensitivity. Overall,
our findings are consistent with the results from NSCLC [19]
and confirm that EPHA3 is involved in regulating the
chemoresistance of SCLC with tumor-suppressing effects.
Considering the observation that re-expression of wild-
type EPHA3 in H1299 cells increased apoptosis by suppres-
sion of AKT activation in vitro [19], as well as that the AKT/
mTOR pathway was upregulated in SCLC, and inhibiting
mTOR signaling with RAD001 potently disrupted growth
and survival signaling in human SCLC cells [47], we pro-
posed the hypothesis that the upstream gene of AKT, PI3K,
may be involved in apoptosis of SCLC cells. Recent studies
show that PIP3 (the product of PI3K) serves as the branching
point for two pathways, the PI3K/AKT/TOR signaling path-
way and the PI3K/BMX/STAT3 signaling pathway, that both
contribute to the oncogenic cellular phenotype. The former
has been studied in great deal, but the latter has not yet been
Fig. 8 EPHA3 inhibited tumor growth of SCLC in vivo. Lower
expression of EPHA3 significantly enhanced the ability of tumor
growth either in H69 cells compared to H69 cells with EPHA3
deficiency or in H69AR, H446, and H146 cells compared to the
corresponding cells with EPHA3 overexpression (a, b). However,
a weak ability of tumor growth was shown in H1688 cells whether the
expression of EPHA3 was upregulated or downregulated. The expression
of EPHA3 in tumor tissues detected by immunohistochemistry (no
staining and strongly positive staining, c) was negatively correlated
with the expression level of p-STAT3 detected by Western blotting (d).
However, no correlation was observed between the expression of
EPHA3 and total STAT3 detected by Western blotting
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identified [20]. To gain insight into the molecular basis of the
role of EPHA3 in modulating MDR potentially through the
PI3K/BMX/STAT3 signaling pathway, we detected the pro-
tein expression of PI3K/BMX/STAT3 in these SCLC cell
lines. Our results suggested that upregulation of EPHA3 in-
hibits the phosphorylation of PI3K/BMX/STAT3 signaling
pathway, especially p85α expression, which is consistent
with the observation that the nSH2 domain of p85 specif-
ically interacts with the kinase domain of EPH receptor
[29]. Furthermore, the expression pattern of p-STAT3 was
negatively correlated with cell apoptosis induced by che-
motherapeutic drugs, which confirmed that EPHA3 could
influence cell apoptosis through PI3K/BMX/STAT3 sig-
naling to modulate MDR in SCLC cells. Moreover, both
PI3K inhibitor LY294002 and BMX inhibitor LFM-A13
reduced the phosphorylation of BMX and/or STAT3 in
the stably EPHA3 silenced SCLC cells, and increased
sensitivity of these cells to chemotherapy drugs, which
coincided with the observation that the survival of the
cisplatin-resistant SCLC cell lines was well suppressed
by BEZ235, accompanied by the suppression of S6RP
phosphorylation [48]. It was noteworthy that the expres-
sion of EPHA3 in tumors was observed to be negatively
correlated with the expression level of p-STAT3, which
was consistent with the results in the cell lines. These
results provided more evidences to show that EPHA3
stimulates apoptosis via PI3K/BMX/STAT3 signaling.
However, our data failed to explain how EPHA3 acts
on PI3K through p85α in SCLC, which need further
research to clarify.
Considerable research has indicated that the PI3K/AKT/
mTOR pathway plays an important role on chemoresistance
Fig. 9 Expression of EPHA3 in diagnostic biopsy samples and the role
of predicted clinical prognosis in SCLC. The expression of EPHA3 in
normal lung tissue samples (72 %) (a) or in SCLC tumor samples
(34.4 %) (b) was detected by immunohistochemistry (200×) with
positive staining site in the cytoplasm. Significant difference was
presented between them (c) For overall survival, the Kaplan–Meier
method revealed that EPHA3 expression level (low (blue), high (red))
(d) and disease stage (LD (blue), ED (red)) (e) were correlated with
significant overall survival time of the 61 SCLC patients. Cox
regression analysis indicated that diseases stage and EPHA3 expression
were found to be significantly independent prognostic factors for the
SCLC patients (f)
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of SCLC. Genetic alterations in the PI3K/AKT/mTOR path-
way were detected in 36 % of the 51 SCLC tumor samples
[48]. TheAKT/mTOR pathwaywas upregulated in SCLC and
RAD001 sensitized human SCLC cells to etoposide [47, 49].
A recent report investigated the antitumor effects of three
mTOR inhibitors including everolimus in 7 SCLC cell lines
and revealed that only SBC5 cells showed sensitivity to evero-
limus. Furthermore, eIF4E was shown to be an important fac-
tor in the resistance to everolimus in SCLC cells, and a link
between MYC and mTOR-independent eIF4E contributed to
the resistance to everolimus in SCLC cells [50]. In view of
these results, we need extendable studies to verify whether
EPHA3 has an impact on downstreamAKT/mTOR signaling.
In summary, our study revealed a coordinated downregu-
lation of EPHA3 gene expression in SCLC multidrug-
resistance cells, whereas upregulation of EPHA3 impaired
chemoresistance by inducing cell apoptosis via the
PI3K/BMX/STAT3 signaling pathway. This study provides a
novel insight into the mechanism of chemoresistance mediat-
ed by EPHA3. Our data suggests that EPHA3 plays a tumor
suppressor role and may be a candidate target for developing
therapeutic strategies to overcome drug resistance in SCLC.
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